Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Rubicon Partners with Diagenode for ChIP Sample Preparation

Published: Monday, November 05, 2012
Last Updated: Sunday, November 04, 2012
Bookmark and Share
Combining Rubicon ThruPLEX™ and Diagenode technologies enables scientists to efficiently conduct high quality ChIP studies from small samples for NGS and array analysis.

Rubicon Genomics, Inc. has announced that it has partnered with Diagenode SA to integrate Rubicon’s ThruPLEX™ technology into Diagenode’s epigenetics platforms to increase the efficiency and quality of DNA sample preparation for chromatin immunoprecipitation (ChIP) applications.

The new agreement allows Diagenode to incorporate the Rubicon ThruPLEX-FD technology into its new MicroPLEX Library Preparation Kit for ChIP-seq studies requiring very small amounts of sample.

Rubicon is a leading provider of sample-specific pre-analytical processes to improve the performance and capabilities of DNA analytical platforms.

Its ThruPLEX-FD NGS Prep kits for synthesis and amplification of ChIP DNA for next generation sequencing (NGS) use a one-tube, three-step process that is efficient, fast, and produces high quality DNA from small samples.

Diagenode’s products increase the efficiency and speed of the process used to precipitate and recover DNA for ChIP applications from very small amounts of chromatin.

The combination of these two patented technologies will decrease the time and labor needed for ChIP-sequencing by almost 10 hours and provide researchers with high quality ChIP-seq and ChIP-chip results from small samples, reducing the number of cells needed to conduct ChIP analyses by a minimum of 100-fold.

“This partnership with Diagenode extends the reach of our proprietary technology. Diagenode is a leader in the ChIP market and our ThruPLEX technology is ideal for use in ChIP studies. This partnership is an important example of our collaboration strategy that focuses on combining complementary technologies to offer complete solutions to the research community,” noted James Koziarz, CEO of Rubicon Genomics.

Rubicon intends to complete additional non-exclusive distribution agreements with leaders in other segments of the growing market for DNA and RNA analysis.

Diagenode has developed and validated reagents and equipment that reduce the number of cells needed to conduct analyses by 10 to 100-fold.

This allows researchers to grow or harvest fewer cells, decreasing time and expense, and also enables studies of small subpopulations of cells.

Combining these properties with the advantages of ThruPLEX-FD increases the quality of the sequencing results and is expected to enhance the value of ChIP as a tool for epigenomic research.

“We are pleased to add the Rubicon ThruPLEX technology to Diagenode’s high quality product line for ChIP studies,” said Didier Allaer, CEO and Founder of Diagenode. “It’s fast, easy-to-use and sensitive, producing high quality results from challenging samples. We will also offer the MicroPLEX and True MicroChIP kits to our customers in conjunction with our new SX-8G IP-Star® Automated System, the first comprehensive system to automate ChIP and DNA methylation assays.”

Rubicon’s ThruPLEX technology incorporates a streamlined one-tube, three-step process without intermediate purifications, transfers, columns or gels. The reduced steps and material transfers decrease the likelihood of experimental variability, bias and contamination.

ThruPLEX technology is designed and validated for use with samples as small as 50 picograms of human DNA and can be used in plasma, FFPE, cDNA, ChIP and population studies.

The kits are currently available for sequencing on Illumina® HiSeq®, MiSeq® and Genome Analyzer instruments. The technology is also being developed for additional formats and platforms.

Both Rubicon and Diagenode will be exhibiting at the Annual Meeting of the American Society for Human Genetics to be held in San Francisco, CA, November 6-10, 2012.

To learn more about Rubicon’s ThruPLEX and its other sample-specific pre-analytical technologies, visit Booth #803, and to learn more about Diagenode’s technologies, visit Booth #406.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Rubicon Genomics Raises $2M
Rubicon Genomics today announced it has secured $2 million in growth capital financing.
Thursday, July 16, 2015
Rubicon Genomics Adds Global Distributors
Sales of Rubicon Genomics’ DNA library prep kit products increase over 50% as expansion of distribution channels continues.
Friday, October 17, 2014
Rubicon Genomics Adds European Distributors Ahead of New Product Launches
Company has signed agreements with seven distributors to expand the availability of its DNA library preparation products.
Saturday, June 14, 2014
New Data Show Rubicon’s Amplification Technology Enables Genetic and Epigenetic Analyses of Single Cells Using Next-Gen Sequencing
Data show Rubicon’s whole genome and whole Methylome Amplification kits offer key advantages for cancer, stem cell, and embryo studies.
Tuesday, November 02, 2010
Rubicon Genomics’ PicoPlex™ Technology Enables International Clinical Genetic Study of Single Human Cells
PicoPlex technology validated for accurate testing of single human cells to diagnose genetic abnormalities in advance of assisted reproduction.
Thursday, July 01, 2010
bicon Genomics, Inc. Creates Scientific Advisory Board

Friday, May 31, 2002
Rubicon Genomics, Inc. Creates Scientific Advisory Board

Friday, May 31, 2002
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos